跳至主要内容
临床试验/NCT06121856
NCT06121856已完成不适用

VerioVue Enhancements Regulatory Clinical Evaluation - Professional Comparison to Validated Method: Arterial Study

LifeScan Scotland Ltd1 个研究点 分布在 1 个国家目标入组 116 人开始时间: 2023年2月7日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
116
试验地点
1
主要终点
Performance evaluation: blood glucose monitoring system accuracy: BGMS vs reference instrument using arterial blood

研究概览

简要总结

The aim of this performance evaluation is to compare the blood glucose results obtained using the VerioVue Blood Glucose Monitoring System (BGMS) with those obtained from a validated comparator method (iSTAT 1 Analyser) using arterial blood. The main question the study aims to answer is:

How accurate is the VerioVue BGMS when compared to a product that has already been confirmed as accurate (iSTAT 1 Analyser) when hospital staff test arterial blood on these two types of instrument? Participants will have a small amount of blood taken from an existing arterial line.

详细描述

Up to two UK NHS hospital sites will be used to collect a minimum of 100 evaluable samples from participants fitted with an arterial line that meet the acceptance criteria. Consent will be obtained from the participants prior to taking part in the study. If the participant meets the enrolment criteria then demographics and medical history information will be collected. A small volume of blood (max 150µl) will be collected from an existing arterial line. The blood will then be applied to six investigational OneTouch VerioVue meters (with expanded haematocrit range 20-65%) fitted with OneTouch Verio test strips and the blood glucose meter readings recorded. Three different lots of test strips will be used in rotation across the study. Within 5 minutes of the last meter test, trained staff will use blood from the same sample and perform a test on the iSTAT Analyser to obtain the blood glucose, haematocrit and oxygen levels of the sample. No treatment decisions will be made based on the blood glucose results obtained for this study. The study documentation will be reviewed by LifeScan monitors for completeness and accuracy and the results entered into a validated database. The data will be extracted and statistically analysed to determine the accuracy of the arterial blood glucose results obtained using the OneTouch VerioVue BGMS when compared to the arterial blood glucose results obtained on the iSTAT 1 Analyser.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Cross Sectional

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age - The potential Subject is at least 16 years old. Language - Subject reads and understands English. Informed Consent - The potential subject must read the Participant Information Sheet and sign the Informed Consent Form.
  • Subject agrees to provide relevant demographic, medical history, and prescription medication information.
  • The subject agrees to allow study staff access to medical records where necessary.
  • The Subject agrees to all aspects of the study process, including arterial blood draws performed by an HCP.

排除标准

  • Age - Subject is under 16 years old. Current Covid-19 positive test result.

结局指标

主要结局

Performance evaluation: blood glucose monitoring system accuracy: BGMS vs reference instrument using arterial blood

时间窗: Within 30 minutes of arterial blood sample draw.

Performance Evaluation to compare the VerioVue BGMS blood glucose results to results obtained using the iSTAT 1 Analyser, a validated comparator method when using arterial blood.

次要结局

未报告次要终点

研究者

发起方
LifeScan Scotland Ltd
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Project VerioVue Enhancements - Arterial Study | 临床试验